Open Access

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

  • Ashish M. Kamat1Email author,
  • Joaquim Bellmunt2,
  • Matthew D. Galsky3,
  • Badrinath R. Konety4,
  • Donald L. Lamm5,
  • David Langham6,
  • Cheryl T. Lee7,
  • Matthew I. Milowsky8,
  • Michael A. O’Donnell9,
  • Peter H. O’Donnell10,
  • Daniel P. Petrylak11,
  • Padmanee Sharma12,
  • Eila C. Skinner13,
  • Guru Sonpavde14,
  • John A. TaylorIII15,
  • Prasanth Abraham16 and
  • Jonathan E. Rosenberg17
Journal for ImmunoTherapy of Cancer20175:80

Received: 30 August 2017

Accepted: 31 August 2017

Published: 28 September 2017

The original article was published in Journal for ImmunoTherapy of Cancer 2017 5:68


After the publication of the article [1], the treatment algorithm for advanced/metastatic bladder cancer in Fig. 3 was updated to reflect the current use of immunotherapy in this setting. The correct Fig. 3 can be seen here and the original article has been updated to reflect this change.
Fig. 3

All of the treatment options shown may be appropriate. The selection of therapy should be individualized based on patient eligibility and the availability of therapy, at the discretion of the treating physician. These algorithms represent the consensus recommendations of the Task Force. (1) Atezolizumab and pembrolizumab are FDA approved for patients with metastatic urothelial carcinoma who are ineligible to receive cisplatin. (2) Atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab are FDA approved for advanced disease that has worsened on platinum containing regimens or within 12 months of receiving a platinum-containing regimen before (neoadjuvant) or after surgery (adjuvant). Abbreviations: dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DDMVAC)



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

University of Texas MD Anderson Cancer Center
Dana-Farber Cancer Institute
Tisch Cancer Institute at Mount Sinai Medical Center
University of Minnesota
BCG Oncology
Bladder Cancer Advocacy Network, North Carolina Triangle Chapter
The Ohio State University Wexner Medical Center
University of North Carolina
University of Iowa
University of Chicago
Yale Cancer Center
University of Texas MD Anderson Cancer Center
Stanford University
University of Alabama
University of Kansas Cancer Center
University of Texas MD Anderson Cancer Center
Memorial Sloan Kettering Cancer Center


  1. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Journal for Immunotherapy of Cancer. 2017;5:68. View ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s). 2017